YARW
Yarrow Bioscience Inc
Healthcare — Biotechnology
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.
None
$23.60
+$1.08 (+4.80%)
Price History
52-Week Range
Sign in to add YARW to a watchlist or set price alerts.
Fundamentals
| Market Cap | - |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | - |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 49.4 |
| Beta | - |
| SMA 20 | $35.30 |
| SMA 40 | $33.97 |
| 52-Week High | $46.95 |
| 52-Week Low | $14.05 |
| 50-Day Avg | $33.91 |
| 200-Day Avg | $28.39 |
| Avg Volume | 17.9K |
| Volume | 8.9K |
Performance Analysis
NEUTRALYARW presents a mixed picture with both positive and negative indicators.
~
Trading at 29% of its 52-week range.
~
RSI at 49.4 is in neutral territory.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Aug 03, 2026 16:00 UTC
Back to Screener Export Report